Aperio Technologies is launching a digital pathology solution for immunohistochemistry (IHC) designed specifically for the clinical market.
Aperio's digital IHC solution is an FDA-cleared system that allows pathologists to run quantitative IHC image analysis while reading slides on a computer monitor.
A digital IHC system streamlines clinical workflow.
By using a single system to read digital IHC slides, perform quantitative image analysis, and create professional reports, pathologists can provide faster turn-around times, more informed decision-making, and accurate and consistent test results.
Eric F Glassy, medical director at Pathology, said: 'After switching to Aperio's digital IHC solution from a different technology, we immediately experienced improved efficiency.
'The interpretation algorithms offer far more control and accuracy, and the reporting capability is superior.
'We especially appreciate the ability to link thumbnail images on the PDF file to the actual whole slide images,' he added.
The digital IHC system includes FDA-cleared algorithms for HER2, ER and PR stained breast specimens for diagnosing digital slides for clinical use in pathology.
In addition, the system comes with a suite of image analysis algorithms that can be tuned for different tissue types (breast, colon, prostate), stains (HER2, ER, PR, Ki-67, P53, EGFR), reagents (Dako, Ventana) or to correlate algorithm results with other test methods (Fish, Cish).
Aperio's digital pathology platform allows laboratories and pathologists to adopt digital pathology in applications such as IHC and then expand the utility of the system to many other digital pathology services such as secondary consultations, tumour boards, quality assurance programmes, plus proficiency testing and training.
